Weekly versus three-weekly docetaxel in women with breast cancer

Conditions

Primary breast cancer Cancer Malignant neoplasm of the breast

Iddawela M, Rueda O, Eremin J, Eremin O, Cowley J, Earl HM, Caldas C.

2017-07-119 citations

Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer.

Walker LG, Eremin JM, Aloysius MM, Vassanasiri W, Walker MB, El-Sheemy M, Cowley G, Beer J, Samphao S, Wiseman J, Jibril JA, Valerio D, Clarke DJ, Kamal M, Thorpe GW, Baria K, Eremin O.

2011-05-1823 citations

10.1186/1471-2407-11-179

Interventions

Arm A: 12 cycles of weekly docetaxel intravenously (IV) 100 mg/m2 for 12 weeks treatment Arm B: 4 cycles of three-weekly docetaxel IV 100 mg/m2 for 4 weeks treatment Follow-up for both arms was 75.5

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Women aged 18 - 70 years 2. Unilateral/bilateral large (greater than or equal to 3 cm) or locally advanced primary breast cancer (T3, T4, TxN2), no distant metastases 3. World Health Organization (WHO) performance status of less than 2 4. Adequate cardiac, haematological, renal, and hepatic function

Exclusion criteria

Exclusion criteria: 1. Pregnant 2. Previous malignancy (except curatively treated carcinoma in situ of the cervix or basal cell carcinoma of skin) 3. Previous cytotoxic, endocrine, or radiotherapy 4. Active infection 5. Contraindications to corticosteroid administration 6. Pre-existing neurotoxicity (greater than grade 2) as defined by the National Cancer Institute Common Toxicity Criteria (NCI-CTC) 7. Significant cognitive impairment or dementia 8. Inability to complete quality of life (QoL) questionnaires or provide informed consent

Design outcomes

Primary

Measure	Time frame
Quality of life 3 weeks after completion of chemotherapy	—

Secondary

Measure	Time frame
1. Clinical and pathological responses at 12 weeks 2. Disease free survival and overall survival at 5 years	—

Countries

United Kingdom

Outcome results

None listed